MarketScreener Homepage > Equities > Nasdaq > ChemoCentryx, Inc. CCXI

Report

Real-time Estimate Cboe BZX - 01/28 11:25:35 am
57.145	USD		+1.36%

01/07

INSIDER TRENDS : Insider at ChemoCentryx Acquires Stock Via Option/Derivative Security Sells Portion to Pay Tax, Buy Trend Intact

01/07

INSIDER TRENDS : Insider at ChemoCentryx Acquires Stock Via Option/Derivative Security, Sells Portion to Pay Tax, Selling Trend Continues

01/06

ChemoCentryx to Participate in Two Upcoming Investor Conferences

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

01/22/2021	01/25/2021	01/26/2021	01/27/2021	01/28/2021	Date
64.4(c)	64.82(c)	59.29(c)	56.38(c)	56.76	Last
564 468	797 488	531 027	811 053	149 113	Volume
+1.77%	+0.65%	-8.53%	-4.91%	+0.67%	Change

More quotes

Financials (USD)

Sales 2020	68,5 M - -
Net income 2020	-48,3 M - -
Net cash position 2020	387 M - -
P/E ratio 2020	-76,7x
Yield 2020	-

Sales 2021	51,4 M - -
Net income 2021	-99,7 M - -
Net cash position 2021	421 M - -
P/E ratio 2021	-39,2x
Yield 2021	-

Capitalization	3 902 M 3 902 M -
EV / Sales 2020	51,3x
EV / Sales 2021	67,8x
Nbr of Employees	82
Free-Float	76,4%

More Financials

Company

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168)...

Sector

Pharmaceuticals

Calendar

03/15

Ergebnisveröffentlichung

More about the company

Notations Surperformance© of ChemoCentryx, Inc.

Trading Rating :

Investor Rating :

More Ratings

All news about CHEMOCENTRYX, INC.

01/07	INSIDER TRENDS : Insider at ChemoCentryx Acquires Stock Via Option/Derivative Se..	MT
01/07	INSIDER TRENDS : Insider at ChemoCentryx Acquires Stock Via Option/Derivative Se..	MT
01/06	ChemoCentryx to Participate in Two Upcoming Investor Conferences	GL
2020	CHEMOCENTRYX : Insider Sale at ChemoCentryx (CCXI) Deemed Significant	MT
2020	INSIDER TRENDS : ChemoCentryx Insider Extends 90-Day Selling Trend	MT
2020	SECTOR UPDATE : Health Care Stocks Flat to Higher on Premarket Tuesday	MT
2020	ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacop..	AQ
2020	ETF PREVIEW : ETFs, Futures Slump Lower as Concerns Over New Strain of COVID-19 ..	MT
2020	ChemoCentryx Kidney Disease Drug Fails to Reach Primary Endpoint in Mid-Stage..	MT
2020	CHEMOCENTRYX : Topline Results of ACCOLADE Trial of Avacopan for C3 Glomerulopat..	PU
2020	CHEMOCENTRYX, INC. : Regulation FD Disclosure, Other Events, Financial Statement..	AQ
2020	ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacop..	GL
2020	Biotechnology Sector's 2020 Cash Stockpile Growth Prepares More Firms to Mana..	MT
2020	CHEMOCENTRYX : to Present at Two Upcoming Investor Conferences	AQ
2020	ChemoCentryx to Present at Two Upcoming Investor Conferences	GL

More news

News in other languages on CHEMOCENTRYX, INC.

2020	Aktien Schweiz Vorbörse: SMI nach Vortagesverlusten leicht erholt erwartet
2020	La coentreprise Vifor-Fresenius présente des résultats de l'étude ACCOLADE
2020	Vifor-Joint-Venture präsentiert erste Ergebnisse der ACCOLADE-Studie
2020	Aktien Schweiz Vorbörse: Am US-Wahltag fester gesehen
2020	Vifor Pharma macht mit Partnern weiteren Schritt mit Avacopan bei EU-Zulassun..

More news

Provided by Scoopnest.com

Chart CHEMOCENTRYX, INC.

Duration : Period :

ChemoCentryx, Inc. Technical Analysis Chart | CCXI | US16383L1061 | MarketScreener

Full-screen chart

Technical analysis trends CHEMOCENTRYX, INC.

	Short Term	Mid-Term	Long Term
Trends	Bearish	Bullish	Neutral

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	BUY
Number of Analysts	7
Average target price	82,14 $
Last Close Price	56,38 $
Spread / Highest target	111%
Spread / Average Target	45,7%
Spread / Lowest Target	6,42%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Thomas J. Schall	Chairman, President & Chief Executive Officer
Susan M. Kanaya	EVP, Chief Financial & Administrative Officer
Catherine Lee Kelleher	Senior Vice President-Clinical Development
Sangita Ghosh	Senior Vice President-Technical Operations
Geoffrey M. Parker	Independent Director

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

CHEMOCENTRYX, INC.	-8.95%	3 902



CSL LIMITED	-2.70%	96 233
SAMSUNG BIOLOGICS CO.,LTD.	-4.36%	50 715
BIOGEN INC.	8.29%	40 802
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.	12.91%	40 785
ALEXION PHARMACEUTICALS, INC.	3.53%	34 072

More Results